KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $102,338 | +7.0% | 10,627 | 0.0% | 0.00% | – |
| Q2 2023 | $95,643 | -35.1% | 10,627 | +4.6% | 0.00% | – |
| Q3 2022 | $147,364 | +42.4% | 10,156 | -3.4% | 0.00% | – |
| Q2 2022 | $103,458 | -32.4% | 10,514 | -9.0% | 0.00% | – |
| Q4 2021 | $153,000 | -21.9% | 11,560 | +2.8% | 0.00% | – |
| Q3 2021 | $196,000 | -30.2% | 11,247 | -4.0% | 0.00% | – |
| Q2 2021 | $281,000 | -0.7% | 11,721 | +6.4% | 0.00% | – |
| Q1 2021 | $283,000 | +14050.0% | 11,012 | +4667.1% | 0.00% | – |
| Q2 2018 | $2,000 | 0.0% | 231 | 0.0% | 0.00% | – |
| Q1 2018 | $2,000 | 0.0% | 231 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | 0.0% | 231 | 0.0% | 0.00% | – |
| Q3 2017 | $2,000 | -33.3% | 231 | -24.5% | 0.00% | – |
| Q2 2017 | $3,000 | 0.0% | 306 | -1.3% | 0.00% | – |
| Q1 2017 | $3,000 | 0.0% | 310 | 0.0% | 0.00% | – |
| Q4 2016 | $3,000 | – | 310 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |